Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better Than Placebo
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better Than Placebo
在 DMX-200 表现优于安慰剂之后，Dimerix 扩大了肾脏药物研究
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册